4521 — Kaken Pharmaceutical Co Income Statement

0.000.00%

Last trade - 00:00

HealthcareConservativeMid CapSuper Stock

Annual income statement for Kaken Pharmaceutical Co, fiscal year end - March 31st, JPY millions except per share, conversion factor applied.

	2020 March 31st	2021 March 31st	2022 March 31st	2023 March 31st	2024 March 31st
Period Length:	12 M	12 M	12 M	12 M	12 M
Source:	Yuho	Yuho	Yuho	Yuho	Yuho
Standards:	JAS	JAS	JAS	JAS	JAS
Status:	Final	Final	Final	Final	Final
Revenue
Total Revenue	89,232	74,979	76,034	72,984	72,044
Cost of Revenue
Gross Profit	50,479	40,906	41,576	39,556	38,539
Selling / General / Administrative Expenses
Research And Development
Depreciation and Amortization
Unusual Expense / Income
Other Operating Expenses
Total Operating Expenses	63,076	57,249	62,830	66,898	62,698
Operating Profit	26,156	17,730	13,204	6,086	9,346
Gain / Loss on Sale of Assets
Total Net Non Operating Interest Income / Expense
Other Net Non Operating Costs
Net Income Before Taxes	26,592	18,657	13,885	6,817	9,796
Provision for Income Taxes
Net Income After Taxes	19,370	13,405	9,549	5,440	8,026
Net Income Before Extraordinary Items
Net Income	19,370	13,405	9,549	5,440	8,026
Adjustments to Net Income
Income Available to Common Shareholders Excluding Extraordinary Items
Income Available to Common Shareholders Including Extraordinary Items
Diluted Net Income	19,370	13,405	9,549	5,440	8,025
Diluted Weighted Average Shares
Basic EPS Including Extraordinary Items
Diluted EPS Including Extraordinary Items
Diluted EPS Excluding Extraordinary Items
Normalised Income Before Taxes
Normalised Income After Taxes
Normalised Income Available to Common Shareholders
Diluted Normalised EPS	501	341	318	186	220
Dividends per Share